Tirzepatide (mounjaro) 5mg 10mg 15mg umjovo

incazelo emfushane:

Igama: Tirzepatide

Imininingwane: 5mg/vial*10vials/box 10mg/vial*10vial/box 15mg/vial*10vial/box

Inani: 5mg USD110/box 10mg USD220/box 15mg USD330/box

Ilebhu: Lianfu Bio

I-MOQ: Ibhokisi elingu-1

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

I-Tirzepatide

I-Tirzepatide iwuphenyo kanye ngesonto, i-insulinotropic polypeptide encike kuglucose ekabili kanye ne-glucagon-like peptide-1 receptor agonist ehlanganisa izenzo zawo womabili ama-incretin zibe ingqamuzana elilodwa.

I-Tirzepatide Mimics Ama-Hormone Emvelo Akhuthaza Ukuzizwa Okugcwele
I-Tirzepatide isebenza ngokulingisa amahomoni e-GLP-1 kanye ne-GIP akhiqizwa amathumbu ngokwemvelo ngemva kokudla, akhuthaza ukukhiqizwa kwe-insulin.Iphinde inciphise isifiso sokudla ngokunciphisa isikhathi esithatha isisu ukuba singabi nalutho futhi ixhumane nezindawo ezisebuchosheni eziphethe ama-GLP-1 receptors ukuze abonise ukusutha.

I-Tirzepatide umuthi wenoveli ogunyazwe yi-FDA ekwelapheni uhlobo 2 sikashukela i-mellitus.Uma kubhekwa izici zayo ezinamandla zokunciphisa isisindo,i-tirzepatidezisetshenziswe ngaphandle kwelebula ekwelapheni ukukhuluphala.Isebenza njenge-agonist ekabili ye-GLP-1 kanye ne-GIP agonist ukukhulisa izinzuzo ezifanayo ezibonwa ngemithi ye-GLP-1 njenge-semaglutide.Njengamanje isetshenziswa njengomuthi wesifo sikashukela somugqa wesibili, ofana nemithi ye-GLP-1, futhi inikezwa njengomjovo ongaphansi kwesikhumba kanye ngesonto.

I-Tirzepatide iyi-insulinotropic polypeptide (GIP) encike ku-glucose kanye ne-glucagon-like peptide-1 (GLP-1) recepto agonist, egunyazwe yi-FDA ekwelapheni uhlobo 2 sikashukela i-mellitus.Kubalulekile ukuqaphela ukuthi i-tirzepatide ayivunyelwe ukwelapha uhlobo-1 sikashukela i-mellitus futhi ayizange ifundwe ezigulini ezine-pancreatitis.I-Tirzepatide iyi-GIP receptor kanye ne-GLP-1 receptor agonist, okuholela ekulawuleni okuthuthukisiwe kwe-glycemic ohlotsheni lwesifo sikashukela sohlobo 2 kanye nokunciphisa umzimba okuphawulekayo.

I-FDA igunyaze i-Tirzepatide ngoMeyi 2022. I-Tirzepatide ingasetshenziswa ngaphandle kwelebula ukwelapha ukukhuluphala.Njengamanje isetshenziswa njengomuthi wesifo sikashukela somugqa wesibili, ofana nemithi ye-GLP-1 efana ne-semaglutide.Kuwumuthi omjovo ongaphansi kwesikhumba wakanye ngeviki onethamo elikhuphukayo.

Idatha yamanje yomtholampilo ibonise ukuthi i-tirzepatide iphakeme kune-placebo ekuthuthukiseni amazinga e-hemoglobin A1C.Ukuhlolwa komtholampilo kwe-SURPASS-5 kubonise ukuncipha kwe--2.11% kumazinga e-hemoglobin A1C ku-5mg nge-dosing yeviki, uma kuqhathaniswa ne--0.86% ne-placebo.Ngesilinganiso esiphezulu se-15 mg ngesonto, i-tirzepatide iholele ekunciphiseni kwe-hemoglobin A1C -2.34%.Lokhu kuboniswe emavikini angama-40.Ukuncipha kwesisindo se-5.4 kg kubonwe nge-5mg ye-tirzepatide dosing, futhi ukuncipha kwe-10.5 kg kubonwe nge-dosing engu-15 mg.Lokhu kuhlotshaniswa okuncike kumthamo nokuncipha kwesisindo kufana ne-semaglutide, umuthi ojwayelekile we-GLP-1 osetshenziselwa ukuphathwa kwesisindo.

Ngokuqhathaniswa, i-tirzepatide ikhonjiswe ukuthi isebenza ngendlela efanayo nemithi ye-GLP-1 kodwa isebenza ngempumelelo kakhulu.Njengoba kunikezwe izakhiwo zayo zokulahlekelwa isisindo kanye nokuntuleka kobuthi besibindi, kungenzeka ukuthi ibambe iqhaza elingaqondile ekwelapheni isifo sesibindi esinamafutha angenalo utshwala (NAFLD) futhi.